Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study

NCT05295394 is registered in ClinicalTrials.gov with Pedro Cahn as lead sponsor.

NCT NCT05295394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05295394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study
Lead sponsor
Pedro Cahn
Phase
Phase 4
Overall status
Withdrawn
Start date
May 22, 2019
Completion date
August 30, 2022
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1 infection